久久久精品无码中文_波多野结衣免费av_精品人妻少妇一区二区_日本无遮挡黄视频大全_男生女生一起相差差差轮滑鞋_真人作爱一级毛片视频免费看_欧美激情综合亚洲五月蜜桃_97色伦午夜免费公开视频

BEIJING, China, March 25, 2026 – On March 13, 2026, Beijing QL Biopharmaceutical Co., Ltd. (QL Biopharm) hosted an investigator’s meeting for its Phase 3 study, HORIZON-1, entitled "A Study of Zovaglutide in Subjects with Overweight or Obesity (HORIZON-1)” (NCT07230119). Among the variations of GLP-1 therapeutics under clinical study, zovaglutide (ZT002) is designed to possess an extended half-life that can support once-monthly dosing.

TAIZHOU, China, December 28, 2025 - On December 26, 2025, Zhitai Pharmaceuticals (Taizhou) Co., Ltd. (QL Pharmaceuticals), a wholly-owned subsidiary of Beijing QL Biopharmaceutical Co, Ltd (QL Biopharm or company), received approval by China's National Medical Products Administration (NMPA) to manufacture commercial material of ZT001, a semaglutide biosimilar. This approval marks a crucial milestone for the company in the field of commercial drug manufacturing for ZT001 and potentially additional programs in QL Biopharm's pipeline.

BEIJING, China, December 12, 2025 - Beijing QL Biopharmaceutical Co., Ltd. (QL Biopharm) dosed its first patient with ZT006, its novel oral GLP-1 receptor agonist (GLP-1 RA), ZT006, in a Phase 2 obesity study.

BEIJING, China, November 23, 2025 - Beijing QL Biopharmaceutical Co., Ltd. (QL Biopharm) dosed its first patient in Australia with ZT003, its innovative GLP-1/FGF21 fusion peptide and dual agonist investigational new medicine.

BEIJING, China, September 17, 2025 – Beijing QL Biopharmaceutical Co., Ltd. (hereafter "QL Biopharm" or the "company") announced today at the European Association for the Study of Diabetes (EASD) annual meeting that its novel experimental therapy in the management of obesity met both its primary and secondary endpoints in a randomized, double-blind, placebo-controlled Phase 2 trial.

On June 27, 2025, ZT003 Injection, an innovative GLP-1/FGF21 dual agonist independently developed by Beijing QL Biopharmaceutical, was officially approved for clinical trial by the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). ZT003 is on track to launch phase I clinical trials abroad, marking a significant step forward in QL Biopharm's international strategy for innovative drugs.